ClinicalTrials.gg
RecruitingNCT06710379Updated Apr 9, 2025

A Study of ADRX-0405 in Subjects With Select Advanced Solid Tumors

A Phase 1 interventional study of ADRX-0405 in Solid Tumors, sponsored by Adcentrx Therapeutics. Recruiting at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-09.

Sponsored by Adcentrx Therapeutics · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Dec 2024; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
68
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The primary purpose of this study is to assess the safety, tolerability, and pharmacokinetics, and to identify the optimal dose of ADRX-0405 in patients with select advanced solid tumors.

Read the detailed description

This is a 2-part study. The Phase 1a will consist of a dose escalation of ADRX-0405 to evaluate initial safety and tolerability in patients with select advanced solid tumors [including metastatic castration resistant prostate cancer (mCRPC), gastric cancer (GC), and non-small cell lung cancer (NSCLC)], and to identify the recommended dose to be used in the Phase 1b. The Phase 1b will further evaluate the safety and tolerability, as well as preliminary efficacy, and identify the optimal dose of ADRX-0405 in subjects with previously treated metastatic castration resistant prostate cancer (mCRPC).

02

Conditions studied

  • Solid Tumors
03

In context

Lead sponsor

Adcentrx Therapeutics is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Phase 1a Dose Escalation: Subjects with confirmed select advanced solid tumors, including castration resistant prostate cancer (mCRPC), gastric cancer (GC), and non-small cell lung cancer (NSCLC).
  • Phase 1b Dose Expansion: Subjects with histologically confirmed prostate adenocarcinoma that is confirmed to be castration resistant (i.e., serum testosterone \< 50 ng/dL [\< 2.0 nM]) and that is intolerant/resistant to standard of care (SOC) therapies.
  • according to version 1.1 or evaluable disease per PCWG3 for subjects with prostate cancer
  • (ECOG) performance status of 0-1 in 1a; 0-2 in 1b
  • Adequate hematologic, liver, and renal function

Exclusion criteria

Exclusion Criteria:

  • Active and uncontrolled central nervous system
  • Significant cardiovascular disease
  • History of another other than the one for which the subject is being treated on this study within 3 years
  • Receipt of any anticancer or therapy within: 5 elimination half-lives or 14 days (whichever is less); 4 weeks for any therapeutic radiopharmaceutical for prostate cancer
  • History of (non-infectious) ILD/pneumonitis that required within 2 years of study enrollment, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.
  • Receiving systemic antimicrobial treatment for active infection; routine antimicrobial prophylaxis is permitted
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
68 participants (estimated)

Study arms

  • Experimental
    Phase 1a Dose Escalation

    Increasing doses of ADRX-0405 will be administered to identify the maximum tolerated dose (MTD) and the recommended dose to be used in the Phase 1b part.

    Drug: ADRX-0405

  • Experimental
    Phase 1b Dose Expansion

    ADRX-0405 will be initially administered at the dose recommended from the Phase 1a part in subjects with previously treated mCRPC.

    Drug: ADRX-0405

Interventions

  • DrugADRX-0405

    Antibody Drug Conjugate targeting STEAP1

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events

    Time frame: Until study completion (estimated 2 years)

Secondary outcomes

  1. Measurement of End of Infusion or observed maximum blood concentration (Ceoi orCmax) of ADRX-0405

    Measured from pharmacokinetic (PK) blood samples

    Time frame: Until study completion (estimated 2 years)

  2. Measurement of trough concentration (Ctrough) of ADRX-0405

    Measured from PK blood samples

    Time frame: Until study completion (estimated 2 years)

  3. Measurement of area under the blood concentration-time curve (AUC) of ADRX-0405

    Measured from PK blood samples

    Time frame: Until study completion (estimated 2 years)

  4. Measurement of partial area under the concentration-time curve after first dose (AUC0-21) of ADRX-0405 and as appropriate

    Measured from PK blood samples

    Time frame: Until study completion (estimated 2 years)

  5. Measurement of terminal or apparent terminal half-life (t1/2) of ADRX-0405

    Measured from PK blood samples

    Time frame: Until study completion (estimated 2 years)

  6. Measurement of systemic clearance (CL) and volume of distribution at steady state (Vss) as appropriate of ADRX-0405

    Measured from PK blood samples

    Time frame: Until study completion (estimated 2 years)

  7. Incidence of anti-drug antibody (ADA) to ADRX-0405

    Measured from ADA blood samples

    Time frame: Until study completion (estimated 2 years)

  8. Measurement of objective response rate (ORR) per RECIST 1.1

    Percentage of subjects achieving complete response (CR) or partial response (PR)

    Time frame: Until study completion (estimated 2 years)

  9. ORR per Prostate Cancer Working Group 3 (PCWG3)

    Percentage of subjects achieving complete response (CR) or partial response (PR)

    Time frame: Until study completion (estimated 2 years)

  10. Measurement of duration of response (DOR)

    Time from first response until first evidence of disease progression (PD) or death from any cause

    Time frame: Until study completion (estimated 2 years)

  11. Measurement of disease control rate (DCR)

    Percentage of subjects achieving CR, PR or stable disease (SD)

    Time frame: Until study completion (estimated 2 years)

  12. Measurement of progression free survival (PFS)

    Time from the start of study drug until first evidence of PD or death from any cause

    Time frame: Until study completion (estimated 2 years)

  13. Measurement of radiographic progression free survival (rPFS)

    Time from the start of study drug until first radiographic documentation of PD, or death from any cause, whichever comes first

    Time frame: Until study completion (estimated 2 years)

  14. Measurement of overall survival (OS)

    Time from the start of study drug until death from any cause

    Time frame: Until study completion (estimated 2 years)

07

Study locations

8 of 8 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2024 (actual). Primary completion is estimated for Jul 2026, 19 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 26, 2024
First posted
Nov 29, 2024
StartActual
Dec 30, 2024
Primary completionEst.
Jul 2026
CompletionEst.
Dec 2026
Last update
Apr 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06710379
Lead sponsor
Adcentrx Therapeutics
Responsible party
Sponsor
First posted
Nov 29, 2024
Start date
Dec 30, 2024
Primary completion
Jul 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Apr 9, 2025

Study contacts

Adcentrx Therapeutics
Contact
clinicaltrials@adcentrx.com
858-428-9502

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion